Argus raised the firm’s price target on Vertex Pharmaceuticals to $350 from $340 and keeps a Buy rating on the shares. The company continues to benefit from strong sales of Trikafta, pipeline progress, and partnerships with other organizations, the analyst tells investors in a research note. Vertex Pharmaceuticals also continues to gain approvals for younger age groups for its cystic fibrosis drugs and to expand the number of countries providing reimbursement coverage for these products, Argus added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?
- Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact
- Vertex Pharmaceuticals initiated with an Outperform at Bernstein
- Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes
- Immunogen confident in early Elahere launch, says Guggenheim